CVS Health Announces Formulary and Therapy Strategy for PCSK9 Inhibitors

By: via Benzinga
CVS Health (NYSE: CVS) announced today that Repatha™ (evolocumab) from Amgen Inc. will be added as the only PCSK9 inhibitor on the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.